衰老生物标志物特征可预测慢性病轨迹、躯体功能与死亡:TILDA与HRS队列验证
高风险特征与12年死亡率升高、8年心血管病、糖尿病、多病共存、衰弱和失能发生率升高及4年躯体功能下降相关,并在美国HRS队列3914人中得到验证。
要点
- 高风险特征与8年多病共存、衰弱、失能及12年死亡风险升高相关。
- 免疫与心血管代谢通路失调可能介导高风险特征相关疾病轨迹。
核心结论
- 多系统血液生物标志物特征可用于风险分层,识别最可能受益于针对性预防或二级干预的衰老亚人群。
研究设计与样本
- 在美国HRS队列3914人中验证结果。
主要发现
- 爱尔兰队列中低风险特征占58.5%、中风险占9.2%、高风险占32.3%。
- 高风险特征与12年死亡率升高相关(HR:1.89,P < .001)。
- 高风险特征与8年心血管病、糖尿病、多病共存、衰弱和失能发生率升高相关(OR范围:1.46-2.49,P < .05)。
- 高风险特征与4年躯体功能较低相关(P < .01)。
- 8年随访识别并追踪6个疾病类别:健康、关节炎、糖尿病/心绞痛、甲状腺功能减退/骨质疏松/呼吸系统、视力/焦虑/心血管病和多系统。
关键数值与推荐
- 高风险生物标志物特征与5个8年新发疾病类别中的2个相关,涉及免疫和心血管代谢通路失调。
临床怎么用
- 可考虑用多系统血液生物标志物特征对老年人群进行风险分层,识别需重点预防或二级干预的亚人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Global population ageing is progressing at an unprecedented rate. Early identification of subpopulations at risk of chronic diseases could mitigate deteriorating health and increasing health service use, while revealing key biological cues and therapeutic targets. We hypothesised that a multisystem biomarker signature could identify future chronic disease trajectories, multimorbidity, functional decline and mortality. METHODS: Eighteen blood biomarkers, representing key systems that become dysregulated with ageing, were assessed among n = 4961 participants aged 50+ years from Ireland. Probabilistic clustering classified participants as belonging to one of three biomarker signatures at baseline. Biomarker signatures were designated as low, medium and high risk based on relative levels of biomarker dysregulation within the signatures and previously described associations with chronic disease and mortality. These biomarker signatures were utilised to predict 4-year functional decline; 8-year cardiovascular disease (CVD), diabetes, frailty, disability and 12-year mortality. Results were validated in a US cohort (n = 3914). RESULTS: Low (58.5%), medium (9.2%) and high-risk (32.3%) biomarker signatures were identified in the cohort from Ireland. The high-risk signature was associated with higher 12-year mortality (HR: 1.89, P < .001); higher 8-year incidence of CVD, diabetes, multimorbidity, frailty and disability (OR range: 1.46-2.49. P < .05); and lower 4-year physical function (P < .01). Findings were corroborated in the US cohort. We identified and tracked 6 disease classes over 8 years: healthy, arthritis, diabetes/angina, hypothyroid/osteoporosis/respiratory, vision/anxiety/CVD and multisystem. Associations between the high-risk biomarker signature and two of the five 8-year incident disease classes were observed, implicating dysregulated immune and cardiometabolic pathways. CONCLUSIONS: This study provides evidence that biomarker signatures and profiling of disease patterns can be used to risk stratify and identify ageing subpopulations that would benefit most from targeted preventative or secondary intervention strategies.
引用
- Hernández B, Klopack E, Moriarty F, et al. An ageing biomarker signature predicts chronic disease cluster trajectories, physical function and mortality: validation in the TILDA and HRS cohorts. Age Ageing. 2026. PMID: 42160766. doi:10.1093/ageing/afag135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。